The U.S. Treasury will begin reviewing its recently introduced rules as part of an executive order signed by President Trump which stipulated that any rules enacted in 2016 and 2017 were to be reviewed for complexity and “undue burdens.” This means that tax inversions may be making a comeback in the pharmaceutical industry. In recent years, these inversions have been the subject of Treasury scrutiny, but may see a sharp rise in activity in 2017 and 2018. This activity could boost industry competition. Read the full article here.
